is to create at least 30 specialised jobs as part of a €50 million investment at its Galway plant over the next three years.group, specialises in neurovascular care. The Galway plant is a research site for stroke where it is developing a portfolio of medical devices to treat the condition.
In Ireland, approximately 7,500 people have a stroke each year, while one third of all strokes happen in people under 65 years of age. Stroke is the biggest cause of acquired disability and the third biggest cause of death in Ireland. The office space has also been expanded to include meeting and collaboration areas, as well as a space to facilitate team and physician collaborations with a focus on research, innovation, and product development., general manager of Cerenovus Galway, said: “Stroke can be a devastating event for patients and their loved ones, and recovery depends on physicians having options to treat patients effectively and efficiently in the hours after their stroke.
“We work closely with universities and academics, including strong collaborations locally with GMIT and. We are committed to developing differentiated solutions based on physicians’ real-world experience of unmet medical needs.